| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NBT824 |
| P953 | full work available at URL | http://www.nature.com/articles/nbt824 |
| http://www.nature.com/articles/nbt824.pdf | ||
| P698 | PubMed publication ID | 12740585 |
| P5875 | ResearchGate publication ID | 10764887 |
| P50 | author | Mark Kay | Q59750959 |
| P2093 | author name string | Hui Xu | |
| Hiroyuki Nakai | |||
| Zan Huang | |||
| Kusum Pandey | |||
| Anton P. McCaffrey | |||
| Felix H. Salazar | |||
| Patricia L. Marion | |||
| Stefan F. Wieland | |||
| P2860 | cites work | Role for a bidentate ribonuclease in the initiation step of RNA interference | Q27860832 |
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| RNA interference | Q28131798 | ||
| Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells | Q28215061 | ||
| An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells | Q29547714 | ||
| High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. | Q33869552 | ||
| Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference | Q34146791 | ||
| Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection | Q34161732 | ||
| Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. | Q34596607 | ||
| Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference | Q39684598 | ||
| Modulation of HIV-1 replication by RNA interference | Q40721798 | ||
| Short interfering RNA confers intracellular antiviral immunity in human cells | Q40721804 | ||
| siRNA-directed inhibition of HIV-1 infection | Q40727988 | ||
| Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells | Q40735249 | ||
| Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system | Q41734970 | ||
| RNA interference in adult mice. | Q43038702 | ||
| Inhibition of hepatitis B virus expression and replication by RNA interference | Q45728501 | ||
| Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. | Q45861628 | ||
| Inhibition of retroviral pathogenesis by RNA interference. | Q52546996 | ||
| Expanding small RNA interference | Q78021693 | ||
| RNA interference targeting Fas protects mice from fulminant hepatitis | Q78961966 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| molecular medicine | Q3523816 | ||
| hepatitis B | Q6853 | ||
| biotechnology | Q7108 | ||
| bioengineering | Q580689 | ||
| RNA interference | Q201993 | ||
| biomedical engineering | Q327092 | ||
| Applied Microbiology and Biotechnology | Q13553694 | ||
| P304 | page(s) | 639-644 | |
| P577 | publication date | 2003-05-12 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Inhibition of hepatitis B virus in mice by RNA interference | |
| P478 | volume | 21 |
| Q40263923 | A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells |
| Q38982303 | A rational study for identification of highly effective siRNAs against hepatitis B virus |
| Q39403031 | A transgenic Marc-145 cell line of piggyBac transposon-derived targeting shRNA interference against porcine reproductive and respiratory syndrome virus |
| Q37825907 | AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? |
| Q35568525 | AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy |
| Q24816212 | Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. |
| Q34417017 | Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication |
| Q36006146 | Adeno-associated virus vectors for short hairpin RNA expression |
| Q38351487 | Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference. |
| Q40245133 | All in the RNA family |
| Q39502368 | Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model |
| Q52576104 | An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. |
| Q40171806 | An RNAi-based high-throughput screening assay to identify small molecule inhibitors of hepatitis B virus replication |
| Q52671153 | Animal models for the study of hepatitis B virus infection. |
| Q30531035 | Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70. |
| Q81772313 | Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors |
| Q36264167 | Antiviral RNAi therapy: emerging approaches for hitting a moving target |
| Q37914065 | Antiviral RNAi: translating science towards therapeutic success |
| Q34223779 | Antiviral treatment of chronic hepatitis B virus (HBV) infections |
| Q37832903 | Application of RNA interference in treating human diseases |
| Q35857297 | Artificial microRNA-mediated virus resistance in plants |
| Q45422183 | Avian metapneumovirus phosphoprotein targeted RNA interference silences the expression of viral proteins and inhibits virus replication |
| Q40595052 | Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. |
| Q44918126 | Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. |
| Q59352117 | Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development |
| Q83963455 | Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma |
| Q33756729 | Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs |
| Q53178845 | Collision-induced dissociation of oligonucleotide anions fully modified at the 2'-position of the ribose: 2'-F/-H and 2'-F/-H/-OMe mix-mers. |
| Q34425073 | Combination of small interfering RNAs mediates greater inhibition of human hepatitis B virus replication and antigen expression |
| Q36181757 | Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice |
| Q33713259 | Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. |
| Q34756517 | Conditional transgenic mouse models: from the basics to genome-wide sets of knockouts and current studies of tissue regeneration. |
| Q42262496 | Construction and application of a novel hepatocyte-directed vector to simultaneous knockdown and overexpression of multiple genes. |
| Q40447828 | Cost-effective method of siRNA preparation and its application to inhibit hepatitis B virus replication in HepG2 cells. |
| Q37931159 | Countering hepatitis B virus infection using RNAi: how far are we from the clinic? |
| Q40155689 | Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor |
| Q35571573 | Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus |
| Q37503380 | Current and future treatments of autoimmune hepatitis |
| Q28235733 | Current prospects for RNA interference-based therapies |
| Q37737316 | Delivery of RNA interference triggers to sensory neurons in vivo using herpes simplex virus |
| Q81255518 | Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection |
| Q89910193 | Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA |
| Q35816825 | Development and optimization of nanosomal formulations for siRNA delivery to the liver |
| Q36322125 | Development of effective therapies against West Nile virus infection |
| Q35932393 | Development of gene-specific double-stranded RNA drugs |
| Q33677072 | Discovery and Development of Anti-HBV Agents and Their Resistance |
| Q33627169 | Drosha as an interferon-independent antiviral factor |
| Q37411584 | Drug targets in hepatitis B virus infection. |
| Q38326093 | Effect of vector-expressed shRNAs on hTERT expression |
| Q36065871 | Effect of vector-expressed siRNA on HBV replication in hepatoblastoma cells |
| Q40342191 | Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs |
| Q35880915 | Effects of length and location on the cellular response to double-stranded RNA. |
| Q37520714 | Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA. |
| Q40323818 | Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice |
| Q33801328 | Emerging antivirals for the treatment of hepatitis B. |
| Q37682722 | Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis |
| Q34775644 | Engineered external guide sequences are highly effective in inhibiting gene expression and replication of hepatitis B virus in cultured cells |
| Q33819100 | Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice |
| Q35811792 | Enhanced inhibition of Avian leukosis virus subgroup J replication by multi-target miRNAs |
| Q38837065 | Eradication Strategies for Chronic Hepatitis B Infection |
| Q40327702 | EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs |
| Q38035173 | Experimental models and therapeutic approaches for HBV. |
| Q36442525 | Experimental models of liver fibrosis |
| Q36033368 | Exploiting the RNA interference pathway to counter hepatitis B virus replication. |
| Q39989261 | Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo |
| Q37117812 | Expression strategies for short hairpin RNA interference triggers |
| Q40468769 | Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA. |
| Q34530552 | Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways |
| Q40228009 | Flow cytometry for assessment of the efficacy of siRNA. |
| Q36062699 | From genome to antivirals: SARS as a test tube. |
| Q38772195 | Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond |
| Q38366585 | Gene therapeutic approaches to inhibit hepatitis B virus replication |
| Q36708296 | Gene therapy for viral hepatitis. |
| Q35842662 | Gene therapy of liver diseases |
| Q36804396 | Genetic association meets RNA interference: large-scale genomic screens for causation and mechanism of complex diseases |
| Q37688945 | Genetically modified mice-successes and failures of a widely used technology |
| Q34123971 | Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells |
| Q30428799 | Harnessing DNA synthesis to develop rapid responses to emerging and pandemic pathogens |
| Q27488744 | Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma |
| Q27490527 | Hepatitis B and Hepatitis C Virus Replication Upregulates Serine Protease Inhibitor Kazal, Resulting in Cellular Resistance to Serine Protease-Dependent Apoptosis |
| Q37137539 | Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro |
| Q33508709 | Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. |
| Q36883851 | Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection |
| Q47266536 | How successful has targeted RNA interference for hepatic fibrosis been? |
| Q33220982 | How will RNAi facilitate drug development? |
| Q36226767 | Hydrodynamic delivery |
| Q35207509 | Hydrodynamic delivery of DNA. |
| Q36958849 | Hydrodynamic gene delivery: its principles and applications |
| Q34156859 | Identification of an effective siRNA target site and functional regulatory elements, within the hepatitis B virus posttranscriptional regulatory element. |
| Q41880914 | Identification of cellular genes showing differential expression associated with hepatitis B virus infection |
| Q37938872 | Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics. |
| Q36821357 | Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model |
| Q64966438 | In Vivo Model Systems for Hepatitis B Virus Research. |
| Q50473508 | In vitro and in vivo suppression of GJB2 expression by RNA interference. |
| Q34365687 | In vivo activity of nuclease-resistant siRNAs |
| Q54645843 | Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. |
| Q40366720 | Inhibition of Anatid Herpes Virus-1 replication by small interfering RNAs in cell culture system. |
| Q40559586 | Inhibition of HBV replication by siRNA in a stable HBV-producing cell line |
| Q39539133 | Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin |
| Q31170002 | Inhibition of Henipavirus infection by RNA interference |
| Q40397298 | Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. |
| Q43035710 | Inhibition of West Nile virus replication by short interfering RNAs. |
| Q44859489 | Inhibition of acid-induced apoptosis by targeting ASIC1a mRNA with short hairpin RNA. |
| Q39172730 | Inhibition of avian leukosis virus subgroup J replication by miRNA targeted against env. |
| Q40180290 | Inhibition of dengue virus entry into target cells using synthetic antiviral peptides |
| Q94660737 | Inhibition of encephalomyocarditis virus replication by shRNA targeting 1C and 2A genes in vitro and in vivo |
| Q45880001 | Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. |
| Q50774425 | Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs. |
| Q34456173 | Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs |
| Q42235235 | Inhibition of hepatitis B virus cccDNA by siRNA in transgenic mice |
| Q37335122 | Inhibition of hepatitis B virus gene expression and replication by artificial microRNA |
| Q39996745 | Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. |
| Q40400198 | Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative |
| Q36883874 | Inhibition of hepatitis B virus gene expression and replication by ribonuclease P. |
| Q34017631 | Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo |
| Q39954594 | Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly |
| Q39953129 | Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. |
| Q45474715 | Inhibition of hepatitis B virus replication in 2.2.15 cells by expressed shRNA. |
| Q35029188 | Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. |
| Q35907037 | Inhibition of hepatitis viral replication by siRNA. |
| Q34514513 | Inhibition of influenza virus production in virus-infected mice by RNA interference |
| Q40198668 | Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs |
| Q82329354 | Inhibition of porcine circovirus type 2 replication in mice by RNA interference |
| Q82539958 | Inhibition of porcine transmissible gastroenteritis virus (TGEV) replication in mini-pigs by shRNA |
| Q40450230 | Inhibition of porcine transmissible gastroenteritis virus infection in porcine kidney cells using short hairpin RNAs targeting the membrane gene. |
| Q40414059 | Inhibition of reporter gene and Iridovirus-tiger frog virus in fish cell by RNA interference |
| Q47874231 | Inhibition of respiratory viruses by nasally administered siRNA. |
| Q35123537 | Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells |
| Q28575354 | Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference |
| Q39869286 | Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir |
| Q27490949 | Inhibition of west nile virus replication by retrovirus-delivered small interfering RNA in human neuroblastoma cells |
| Q91900468 | Inhibition of white spot syndrome virus in Litopenaeus vannamei shrimp by sequence-specific siRNA |
| Q39907819 | Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression |
| Q34234252 | Interfering with disease: opportunities and roadblocks to harnessing RNA interference |
| Q34311548 | Interfering with hepatitis C virus RNA replication |
| Q40124825 | Interleukin-1beta is the primary initiator of pulmonary inflammation following liver injury in mice. |
| Q34102905 | Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition |
| Q40492195 | Knockdown of mouse adult beta-globin gene expression in MEL cells by retrovirus vector-mediated RNA interference |
| Q45874854 | Knocking down human disease: potential uses of RNA interference in research and gene therapy |
| Q24806000 | L1 retrotransposon-mediated stable gene silencing |
| Q37425606 | Lipid-based systemic delivery of siRNA. |
| Q92153785 | Lipopeptide Delivery of siRNA to the Central Nervous System |
| Q46250876 | Lipopeptide delivery of siRNA to the central nervous system |
| Q33608651 | Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures |
| Q87669646 | Liver fibrosis |
| Q37987860 | Living in the liver: hepatic infections |
| Q40240165 | Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. |
| Q39686882 | Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1. |
| Q36773747 | Management of hepatitis B: summary of a clinical research workshop |
| Q35669529 | Mechanisms of hepatitis C virus infection |
| Q26773183 | MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations |
| Q57494795 | Mouse models for hepatitis B virus research |
| Q27002598 | Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions |
| Q45862602 | Multifunctional PEI-entrapped gold nanoparticles enable efficient delivery of therapeutic siRNA into glioblastoma cells. |
| Q33866902 | N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication |
| Q45130525 | New targets and inhibitors of HBV replication to combat drug resistance |
| Q38725759 | New therapies for chronic hepatitis B. |
| Q37338992 | Nucleic acids-based therapeutics in the battle against pathogenic viruses |
| Q40240936 | Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA |
| Q30353665 | Oligonucleotide-based antiviral strategies. |
| Q55365677 | One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors. |
| Q36852196 | Opportunities for treating chronic hepatitis B and C virus infection using RNA interference |
| Q24671047 | Optimization of feline immunodeficiency virus vectors for RNA interference |
| Q40587272 | PEG-PLA nanoparticles facilitate siRNA knockdown in adult zebrafish heart |
| Q52100726 | Peers rally in support of accused scientist. |
| Q40723068 | Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches |
| Q36150428 | Polycation-mediated delivery of siRNAs for prophylaxis and treatment of influenza virus infection |
| Q47546902 | Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension |
| Q36378278 | Present and future therapies of hepatitis B: From discovery to cure |
| Q33865784 | Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection. |
| Q56877969 | Progress toward the therapy of hepatitis with RNAi |
| Q34514565 | Protection against lethal influenza virus challenge by RNA interference in vivo. |
| Q45366447 | Protection of shrimp against white spot syndrome virus (WSSV) with β-1,3-D-glucan-encapsulated vp28-siRNA particles |
| Q36065628 | Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR. |
| Q45372948 | RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus |
| Q33653027 | RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo |
| Q35779514 | RNA interference |
| Q40151467 | RNA interference against hepatitis B virus with endoribonuclease-prepared siRNA despite of the target sequence variations |
| Q34655478 | RNA interference against viruses: strike and counterstrike |
| Q36944914 | RNA interference and antiviral therapy. |
| Q35600819 | RNA interference and mRNA silencing, 2004: how far will they reach? |
| Q28250480 | RNA interference and potential therapeutic applications of short interfering RNAs |
| Q35802959 | RNA interference as a new strategy against viral hepatitis. |
| Q36508943 | RNA interference for antiviral therapy |
| Q42048191 | RNA interference in mammalia cells by RNA-3'-PNA chimeras |
| Q40217527 | RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells |
| Q40398853 | RNA interference inhibits yellow fever virus replication in vitro and in vivo |
| Q39833171 | RNA interference targeted to the conserved dimerization initiation site (DIS) of HIV-1 restricts virus escape mutation |
| Q35819608 | RNA interference targeting virion core protein ORF095 inhibits Goatpox virus replication in Vero cells |
| Q36076736 | RNA interference technologies for understanding and treating neurodegenerative diseases |
| Q42272671 | RNA interference with special reference to combating viruses of crustacea |
| Q38076055 | RNA interference--a silent but an efficient therapeutic tool |
| Q35964876 | RNA interference--small RNAs effectively fight viral hepatitis |
| Q40447169 | RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. |
| Q36519038 | RNA interference-mediated prevention and therapy for hepatocellular carcinoma |
| Q41848470 | RNA interference: A futuristic tool and its therapeutic applications |
| Q37102336 | RNA interference: an emerging generation of biologicals |
| Q36440302 | RNA interference: its use as antiviral therapy. |
| Q35739892 | RNA silencing in viral infections: insights from poliovirus |
| Q35739901 | RNA silencing of rotavirus gene expression |
| Q37566034 | RNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside |
| Q79970322 | RNAi and siRNA |
| Q36412870 | RNAi for treating hepatitis B viral infection |
| Q34735628 | RNAi induces innate immunity through multiple cellular signaling pathways |
| Q45723356 | RNAi puts a lid on virus replication |
| Q34621268 | RNAi therapeutics: principles, prospects and challenges |
| Q35996300 | RNAi, a new therapeutic strategy against viral infection |
| Q42249502 | RNAi-based inhibition of porcine reproductive and respiratory syndrome virus replication in transgenic pigs |
| Q37866632 | RNAi-based therapeutic strategies for metabolic disease |
| Q42663848 | RNAi-induced targeted silencing of developmental control genes during chicken embryogenesis. |
| Q34379366 | RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo |
| Q37871417 | RNAi: a potential new class of therapeutic for human genetic disease |
| Q37405760 | Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency |
| Q38687338 | Recent developments in antivirals against hepatitis B virus |
| Q35842500 | Recent developments in target identification against hepatitis C virus |
| Q47616266 | Receptor-targeted siRNAs |
| Q38289404 | Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication |
| Q36800000 | Review of the application of RNA interference technology in the pharmaceutical industry |
| Q39283443 | Role of non-structural protein 2 in the regulation of the replication of the porcine reproductive and respiratory syndrome virus in MARC-145 cells: effect of gene silencing and over expression |
| Q33907953 | Self-assembled lipid nanomedicines for siRNA tumor targeting. |
| Q40368999 | Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference |
| Q40433218 | Short hairpin RNA targeted to the highly conserved 2B nonstructural protein coding region inhibits replication of multiple serotypes of foot-and-mouth disease virus |
| Q40585048 | Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference |
| Q36093470 | Silencing viruses by RNA interference |
| Q40194946 | Simultaneously inhibition of HIV and HBV replication through a dual small interfering RNA expression system. |
| Q63407942 | Slicing and dicing viruses: antiviral RNA interference in mammals |
| Q34274630 | Small interfering RNA Inhibits Hepatitis B virus replication in mice |
| Q46398414 | Small interfering RNA-mediated functional silencing of vasopressin V2 receptors in the mouse kidney |
| Q39299316 | Small interfering RNAs targeting the rabies virus nucleoprotein gene |
| Q90195884 | Sonoporation as an Approach for siRNA delivery into T cells |
| Q40184725 | Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. |
| Q42620818 | Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs |
| Q39427920 | Stability of lyophilized siRNA nanosome formulations |
| Q40480264 | Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. |
| Q91908886 | Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses |
| Q34308129 | Strategies to eliminate HBV infection |
| Q38473640 | Strategies to prevent and reverse liver fibrosis in humans and laboratory animals |
| Q37105696 | Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference |
| Q28582335 | Study of RNA interference inhibiting rat ovarian androgen biosynthesis by depressing 17alpha-hydroxylase/17, 20-lyase activity in vivo |
| Q34124455 | Targeted disruption of outer limiting membrane junctional proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor precursors into the adult wild-type and degenerating retina. |
| Q40114371 | Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery |
| Q36653655 | Targets of emerging therapies for viral hepatitis B and C. |
| Q36740829 | The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. |
| Q37140008 | The potential of RNA interference-based therapies for viral infections |
| Q36002359 | The role of small RNAs in human diseases: potential troublemaker and therapeutic tools |
| Q36362370 | The silent treatment: siRNAs as small molecule drugs |
| Q38660339 | The state of gene therapy research in Africa, its significance and implications for the future. |
| Q36237868 | The therapeutic potential of RNA interference |
| Q37809086 | Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators |
| Q35684854 | Therapeutic potential of retroviral RNAi vectors |
| Q37507085 | Therapeutic regulation of gene expression in the inner ear using RNA interference |
| Q36384459 | Therapeutic short hairpin RNA expression in the liver: viral targets and vectors |
| Q24793831 | Towards in vivo application of RNA interference - new toys, old problems |
| Q35220727 | Transplacental RNAi: deciphering gene function in the postimplantation-staged embryo |
| Q38794446 | Treatment of hepatitis B virus: an update |
| Q40116108 | Two approaches to construct mammalian expression vector of shRNA to reduce expression and replication of HBV in vitro |
| Q37718183 | Type I Interferons Impede Short Hairpin RNA-Mediated RNAi via Inhibition of Dicer-Mediated Processing to Small Interfering RNA. |
| Q51791214 | Unlocking the money-making potential of RNAi. |
| Q34348958 | Unlocking the potential of the human genome with RNA interference |
| Q37747148 | Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice |
| Q34184400 | Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus |
| Q35739898 | Use of siRNAs to prevent and treat influenza virus infection |
| Q39979308 | Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts |
| Q38699649 | Viral life cycle of hepatitis B virus: Host factors and druggable targets |
| Q34327430 | siRNA delivery for the treatment of ovarian cancer |
| Q80701451 | siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection |
| Q39383106 | siRNA relieves chronic neuropathic pain |
| Q45496781 | siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. |
| Q34360881 | siRNA therapeutics: big potential from small RNAs |
| Q40513757 | siRNA-mediated inhibition of HBV replication and expression |
| Q34310668 | siRNAs: applications in functional genomics and potential as therapeutics |
| Q27694682 | siRNAs: potential therapeutic agents against hepatitis C virus |
Search more.